Risk factor
Very high price volatility
Profitability factor
Very favourable analyst view
About
BioCorRx Inc. (BICX), through its various operations, is dedicated to creating and delivering therapeutic solutions for individuals struggling with substance dependence and related health conditions across the United States. Among its core offerings is the BioCorRx recovery program, an innovative, non-addictive treatment model. This program uniquely combines proprietary naltrexone implants with extensive counseling services to support patient recovery. Additionally, the company provides the UnCraveRx weight management program, a medically supported initiative designed to curb food cravings. This program integrates pharmacological assistance with readily available virtual support focusing on lifestyle adjustments, fitness, and nutritional guidance. Looking to the future, BioCorRx is actively advancing its product pipeline. This includes BICX101, an injectable naltrexone product, and BICX104, an implantable naltrexone device, both currently under development for the specific treatment of opioid addiction and alcoholism. The company's programs are made available to patients through a network of healthcare providers, independent licensed clinics, and other qualified healthcare professionals. Originally established as Fresh Start Private Management, Inc., the organization officially rebranded as BioCorRx Inc. in January 2014. Its corporate headquarters are situated in Anaheim, California.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.